USO 24299

A Single-Arm, Phase 2 Study of Neoadjuvant Carboplatin and Mirvetuximab Soravtansine in Subjects with FRα-Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer(M25-231)

Disease Types: GYN Cancer Research

Eligibility Requirements:

• Biopsy-confirmed high-grade serous epithelial ovarian, fallopian tube, or
primary peritoneal cancer
• FIGO Stage III or IV
• FRα-positive (IHC ≥75% of viable tumor cells with 2+/3+) using Ventana
FOLR1 assay
• Pts with BRCA mutations are eligible
• Measurable disease by RECIST v1.1
• No prior systemic anti-cancer therapy other than 1 cycle of single-agent
carboplatin
• Pts who receive cycle of single agent carboplatin must have
baseline radiologic tumor assessment performed at least 2 weeks
after the dose of carboplatin
• Prior treatment with MIRV or other FRα-targeting agents excluded

For more information on this trial CLICK HERE .

Available at:

• Chesapeake
• Newport News (Port Warwick III)
• Norfolk (Brock Cancer Center)